| Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
TORONTO, Nov. 14 /PRNewswire/ -- A Canadian study on High Intensity Focused Ultrasound therapy with the Sonablate(R) 500 - a Health Canada approved treatment for localized prostate cancer - is underway at Can-Am HIFU. Through funding from AstraZeneca Canada Inc, Can-Am HIFU, a prostate cancer treatment centre, will conduct an REB/Health Canada approved clinical trial. The objective of the study is to supplement current research findings on safety and efficacy of HIFU therapy in the treatment of localized prostate cancer. The trial will measure both the biochemical (PSA) cure rates and the Biopsy-proven cure rates at one year. "AstraZeneca is committed to promoting excellence in Canadian health science research and to supporting the growth of Canada's scientific community," says Marc Zarenda, Scientific Director - Oncology at AstraZeneca Canada Inc.
The 10 Most Popular Stories In 2007 From EurekAlert!
Global climate change was a leading topic of interest for EurekAlert! users in 2007. This interest was reflected through two stories that portrayed significantly different messages about the future of Earth's climate.
The EurekAlert! 10 Most Popular Stories in 2007 were identified by monitoring Web site traffic and isolating the news releases that received the highest total number of visits between January and December of 2007. The most popular story of the year received over 180,000 visits.
Aside from global climate change, other topics of most interest to users included studies into the health risks associated with prostate cancer and rheumatoid arthritis, the prevention of Down syndrome, new theories involving matter and the speed of light, the discovery of a dinosaur species in Antarctica, and gender differences across a range of activities from the handling of anxiety to pornography use.
Ranbaxy and Astellas/Boehringer Ingelheim Enter Into an Agreement to ...
Patent No. 4,703,063 ('063 patent), covering Tamsulosin and its use in the treatment for functional symptoms of BPH (benign prostatic hyperplasia). Under the agreement, Ranbaxy will enter the U.S. market on March 2, 2010, eight weeks prior to expiration of the pediatric exclusivity, which is likely to be granted to the innovator company. During this time period of pediatric exclusivity, Ranbaxy will be the only generic manufacturer to commercialize this product in the U.S. market. Ranbaxy believes that its Tamsulosin ANDA is the first substantially complete ANDA with a Paragraph IV certification to the '063 patent. The total annual sales of Flomax are estimated to be USD 1.2 Bn (source IMS). On June 20, 2007, Ranbaxy received tentative approval from the U.S. FDA in regards to its Tamsulosin ANDA No.
|
